drugset / Trial / NCT05555706
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase 2/3
Completed
62 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Timeline
- Start
- 2022-12-06
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B013 | Unknown | 600 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | — |